Annals of Hematology

, Volume 85, Issue 9, pp 631–632

Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab

Authors

    • Department of Internal Medicine IIKlinikum Aschaffenburg
    • I. Medizinische KlinikGP-Klinikum Rüsselsheim
  • Sabine Hainke
    • Department of Internal Medicine IIKlinikum Aschaffenburg
  • Wolfgang Fischbach
    • Department of Internal Medicine IIKlinikum Aschaffenburg
Letter to the Editor

DOI: 10.1007/s00277-006-0147-8

Cite this article as:
Flieger, D., Hainke, S. & Fischbach, W. Ann Hematol (2006) 85: 631. doi:10.1007/s00277-006-0147-8

Copyright information

© Springer-Verlag 2006